Europe 'panicking' over India's pharmaceutical export curbs - industry group
Reuters
Published Mar 04, 2020 08:39
Europe 'panicking' over India's pharmaceutical export curbs - industry group
By Neha Dasgupta
NEW DELHI (Reuters) - India's top pharmaceuticals export group said the government's curbs on some drug exports amid the spreading coronavirus outbreak has caused panic in Europe and will "severely impact" businesses in the sector.
India, the world's main supplier of generic drugs, has restricted the export of 26 active pharmaceutical ingredients (APIs) and the medicines made from them, in a move seen aimed at tackling possible domestic shortages of medicine during the outbreak.
On Wednesday, Dinesh Dua, chairman of the Pharmaceuticals Export Promotion Council of India (Pharmexcil), told Reuters that some of the restricted APIs and medicines were widely exported to Europe and the United States.
"I am getting a huge number of calls from Europe because it is very sizeably dependent on Indian formulations and we control almost 26% of the European formulations in the generic space. So they are panicking," Dua said.
India's list of restricted medicines account for 10% of its total pharmaceutical exports and includes several antibiotics, as well as Paracetamol, a common pain reliever also sold as acetaminophen.
The Food and Drug Administration in the United States, where Indian imports accounted for 24% of medicines in 2018, said on Tuesday it was working to determine how the restrictions will affect U.S. supplies.
The restrictions could hurt India's image as a pharmacy to the world and would impact shipments which were already lined up for export at warehouses and ports, Pharmexcil argued in a letter to India's Directorate General of Foreign Trade (DGFT), which was reviewed by Reuters.
The DGFT did not respond to a request for comment.
"The exporters not only suffer the monetary losses but also their credibility and reputation in international market is at stake," said the letter, which urged the government to allow exports of drugs manufactured before the restrictions kicked in.
"(This) would severely impact our members."
Dua told Reuters there were $10 million (7.8 million pounds) worth of drugs currently at Indian ports or close to being readied for export.
Pharmexcil counts dozens of pharmaceutical firms such as Pfizer Ltd (NS:PFIZ) and Abbott (NS:ABOT) among its members. The council falls under the federal commerce ministry.
Novartis AG (S:NOVN) said on Wednesday it was monitoring the changes in Indian export policy and will "adapt measures as the situation evolves", though the company does not anticipate a supply chain disruption as of now.
Get The App
Indian drugmakers rely on China, the source of the virus outbreak, for almost 70% of the APIs for their medicines. Industry experts say they are likely to face shortages if the coronavirus epidemic drags on.
India - which has so far confirmed 28 cases of the coronavirus, including 16 Italians - has urged calm and said there were enough stocks to manufacture formulations for two to three months.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.